Specific immunotherapy

British Medical Bulletin

Volumn 56, Issue 4, 2000, Pages 1019-1036

  Larché, Mark ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; DNA VACCINE;

ALLERGY; ATOPY; CHRONIC DISEASE; DESENSITIZATION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; PALLIATIVE THERAPY; PREVALENCE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ALLERGENS; ANIMALS; BRONCHIAL PROVOCATION TESTS; CLONAL ANERGY; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; PEPTIDE FRAGMENTS; POACEAE; POLLEN; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL; TH1 CELLS; TH2 CELLS; VACCINES, DNA;

EID: 0034442058     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1258/0007142001903517     Document Type: Review

References (88)

1. Prophylactic inoculation against hay fever
2. Vaccination against hay fever: Report of results during the first three years
3. Prophylaxis of summer hayfever and asthma. A controlled trial comparing crude grass pollen extracts with the isolated main protein component
4. Allergen immunotherapy: Therapeutic vaccines for allergic diseases
5. Immunologic changes associated with allergen immunotherapy
6. Position paper on allergen immunotherapy. Report of a BSACI working party
7. Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs. Description of the model and local airway inflammation
8. Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators
9. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes
10. Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics
11. + T-cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and non atopic (intrinsic) asthmatics
12. Molecular regulation of the IgE immune response
13. Normal human immunoglobulin G4 is bispecific: It has two different antigen-combining sites
14. 2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and non-specific activation of T and B cells
15. Role of interleukin 10 in specific immunotherapy
16. IgE versus IgG4 production can be differentially regulated by IL-10
17. 2 induces specific T-cell anergy in patients allergic to bee venom
18. IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells
19. Grass pollen immunotherapy decreases the number of mast cells in the skin
20. The effect of immunotherapy on the cutaneous late phase response to antigen
21. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses
22. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity
23. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro
24. Inhibition of IgE production and normalization of airways responsiveness by sensitized CD8 T-cells in a mouse model of allergen-induced sensitization
25. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
26. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: Two key steps in specific immunotherapy
27. IL-10: Evolving concepts
28. + T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model
29. + T cell responses: The alternative approaches
30. Studies on 'allergoids' prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group component
31. Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever
32. Controlled evaluation of allergoid in the immunotherapy of ragweed hay fever
33. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract
34. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy
35. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma
36. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids, IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid
37. Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever
38. Immunotherapy with an alumadsorbed Parietaria-pollen allergoid: A 2-year, double-blind, placebo-controlled study
39. Effects of one-year hyposensitization in allergic rhinitis. Comparison of two house dust mite extracts
40. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis
41. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: Potential use of hypoallergenic isoforms for immunotherapy
42. Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE-binding properties
43. Four recombinant isoforms of Cor a 1, the major allergen of hazel pollen, show different reactivities with allergen-specific Tlymphocyte clones
44. Modulation of IgE reactivity of allergens by site-directed mutagenesis: Potential use of hypoallergenic variants for immunotherapy
45. Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2
46. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: Contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2
47. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy
48. 'Allergen engineering': Variants of the timothy grass pollen allergen Phi p 5b with reduced IgE-binding capacity but conserved T cell reactivity
49. Gene vaccination: Plasmid DNA is more than just a blueprint
50. Synthetic oligonucleotides with certain palindromic sequences stimulate interferon production of human peripheral blood lymphocytes in vitro
51. CpG motifs in bacterial DNA trigger direct B cell activation
52. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha
53. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon-γ
54. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
55. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation and airway hyperresponsiveness in mice
56. Inhibition of specific IgE response in vivo by allergen-gene transfer
57. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization
58. Mucosal IFN-gamma gene transfer inhibits pulmonary allergic responses in mice
59. Strain-dependent induction of allergic sensitization caused by peanut allergen DNA immunization in mice
60. Molecular components of T-cell recognition
61. Co-stimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy
62. Co-stimulation through CD86 is involved in airway presenting cell and T cell responses to allergen in atopic asthmatics
63. T cell clonal anergy
64. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin
65. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fei d I
66. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice
67. The specificity and regulation of T-cell responsiveness to allergens
68. Peptide-induced non-responsiveness of HLA-DP restricted human T-cells reactive with Dermatophagoides spp. (house dust mite)
69. Treatment of cat allergy with T-cell reactive peptides
70. Effects of peptide therapy on ex vivo T-cell responses
71. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T-cells of patients allergic to cats
72. Fei d 1 peptides: Effect on skin tests and cytokine synthesis in cat-allergic human subjects
73. The safety and efficacy of ALLERVAX CAT in cat allergic patients
74. 2 induces specific T-cell anergy in patients allergic to bee venom
75. IgE-independent MHC-restricted T cell peptide epitope-induced late asthmatic reactions
76. HLA-DR restricted peptide candidates for bee venom immunotherapy
77. Induction and characterisation of TGFβ secreting Th3 cells
78. + T-cells
79. Transforming growth factor beta (TGF-beta)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell lines
80. T cell suppression in transplantation tolerance through linked suppression
81. Anergic T-cells as suppressor cells in vitro
82. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
83. Amelioration of experimental autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy
84. Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen
85. Prevention of insulin-dependent diabetes mellitus in nonobese diabetic mice by immunogenic but not tolerated peptides
86. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope
87. Peptide-specific prevention of experimental allergic encephalomyelitis
88. Characterization of the specificity and duration of T cell tolerance to intranasally administered peptides in mice: A role for intramolecular epitope suppression